Literature DB >> 10603619

Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.

F Barkhof1, M van Walderveen.   

Abstract

Nuclear magnetic resonance (NMR) imaging is an established diagnostic medium to diagnose multiple sclerosis (MS). In clinically stable MS patients, NMR detects silent disease activity, which is the reason why it is being used to monitor treatment trials, in which it serves as a secondary outcome parameter. The absence of a clear correlation with clinical disability, the so-called 'clinico-radiological' paradox, and the poor predictive value of NMR prohibit the use of NMR as a primary outcome parameter in clinical trials. This is--among others--a result of the limited histopathological specificity of conventional, or 'T2-weighted' imaging, the most commonly used NMR technique. In this paper we review additional NMR techniques with higher tissue specificity, most of which show marked heterogeneity within NMR-visible lesions, reflecting histopathological heterogeneity. Gadolinium enhancement identifies the early inflammatory phase of lesion development, with active phagocytosis by macrophages. Persistently hypointense lesions on T1-weighted images ('black holes') relate to axonal loss and matrix destruction, and show a better correlation with clinical disability. Marked prolongation of T1 relaxation time correlates with enlargement of the extracellular space, which occurs as a result of axonal loss or oedema. Axonal viability can also be measured using the concentration of N-acetyl aspartate (NAA) using NMR spectroscopy; this technique is also capable of showing lactate and mobile lipids in lesions with active macrophages. The multi-exponential behaviour of T2 relaxation time in brain white matter provides a tool to monitor the myelin water component in MS lesions (short T2 component) as well as the expansion of the extracellular space (long T2 component). Chemical exchange with macromolecules (e.g. myelin) can be measured using magnetization transfer imaging, and correlates with demyelination, axonal loss and matrix destruction. Increased water diffusion has been found in MS lesions (relating to oedema and an expanded extracellular space) and a loss of anisotropy may indicate a loss of fibre orientation (compatible with demyelination). Apart from the histopathological heterogeneity within focal MS lesions, the normal-appearing white matter shows definite abnormalities with all quantifiable NMR techniques. A decrease in the concentration of NAA, decreased magnetization transfer values and prolonged T1 relaxation time values are probably all related to microscopic abnormalities, including axonal damage. This 'invisible' lesion load may constitute a significant proportion of the total lesion load but is not visible on conventional NMR. Similarly, mechanisms for clinical recovery exist, which are not distinguished using MR imaging. Therefore, it is highly unlikely that the clinico-radiological paradox will ever be solved completely. However, NMR provides an opportunity to sequentially measure tissue changes in vivo. Using MR parameters with (presumed) histopathological specificity, the development of (irreversible) tissue damage can be monitored, which perhaps allows the identification of factors that determine lesional outcome in MS. Since the absence of severe tissue destruction is prognostically favourable, NMR monitoring of the extent to which such changes can be prevented by treatment will ultimately benefit the selection of future treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10603619      PMCID: PMC1692677          DOI: 10.1098/rstb.1999.0511

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  84 in total

1.  The characterization of experimental gliosis by quantitative nuclear magnetic resonance imaging.

Authors:  D Barnes; W I McDonald; D N Landon; G Johnson
Journal:  Brain       Date:  1988-02       Impact factor: 13.501

2.  Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy.

Authors:  M E Moseley; Y Cohen; J Mintorovitch; L Chileuitt; H Shimizu; J Kucharczyk; M F Wendland; P R Weinstein
Journal:  Magn Reson Med       Date:  1990-05       Impact factor: 4.668

3.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

4.  In vivo determination of T1 and T2 in the brain of patients with severe but stable multiple sclerosis.

Authors:  H B Larsson; J Frederiksen; L Kjaer; O Henriksen; J Olesen
Journal:  Magn Reson Med       Date:  1988-05       Impact factor: 4.668

5.  Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.

Authors:  A J Thompson; A G Kermode; D G MacManus; B E Kendall; D P Kingsley; I F Moseley; W I McDonald
Journal:  BMJ       Date:  1990-03-10

6.  Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease.

Authors:  D L Arnold; P M Matthews; G Francis; J Antel
Journal:  Magn Reson Med       Date:  1990-04       Impact factor: 4.668

7.  Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo.

Authors:  S D Wolff; R S Balaban
Journal:  Magn Reson Med       Date:  1989-04       Impact factor: 4.668

8.  NMR changes in experimental allergic encephalomyelitis: NMR changes precede clinical and pathological events.

Authors:  J T O'Brien; J H Noseworthy; J J Gilbert; S J Karlik
Journal:  Magn Reson Med       Date:  1987-08       Impact factor: 4.668

9.  Assessment of demyelination, edema, and gliosis by in vivo determination of T1 and T2 in the brain of patients with acute attack of multiple sclerosis.

Authors:  H B Larsson; J Frederiksen; J Petersen; A Nordenbo; I Zeeberg; O Henriksen; J Olesen
Journal:  Magn Reson Med       Date:  1989-09       Impact factor: 4.668

10.  Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers.

Authors:  C P Hawkins; P M Munro; F MacKenzie; J Kesselring; P S Tofts; E P du Boulay; D N Landon; W I McDonald
Journal:  Brain       Date:  1990-04       Impact factor: 13.501

View more
  15 in total

1.  In vivo quantitative evaluation of brain tissue damage in multiple sclerosis using gradient echo plural contrast imaging technique.

Authors:  Pascal Sati; Anne H Cross; Jie Luo; Charles F Hildebolt; Dmitriy A Yablonskiy
Journal:  Neuroimage       Date:  2010-03-23       Impact factor: 6.556

2.  Adaptive metabolic changes in CADASIL white matter.

Authors:  Tamar Akhvlediani; Anke Henning; Peter S Sándor; Peter Boesiger; Hans H Jung
Journal:  J Neurol       Date:  2009-08-19       Impact factor: 4.849

3.  Extratemporal damage in temporal lobe epilepsy: magnetization transfer adds information to volumetric MR imaging.

Authors:  P R B Diniz; T R Velasco; C E G Salmon; A C Sakamoto; J P Leite; A C Santos
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-01       Impact factor: 3.825

4.  Brain atrophy correlates with functional outcome in a murine model of multiple sclerosis.

Authors:  I Pirko; A J Johnson; Yi Chen; D M Lindquist; A K Lohrey; J Ying; R Scott Dunn
Journal:  Neuroimage       Date:  2010-09-15       Impact factor: 6.556

5.  Evaluation of normal appearing white matter in multiple sclerosis: comparison of diffusion magnetic resonance, magnetization transfer imaging and multivoxel magnetic resonance spectroscopy findings with expanded disability status scale.

Authors:  Y Anik; A Demirci; H Efendi; S S D Bulut; I Celebi; S Komsuoglu
Journal:  Clin Neuroradiol       Date:  2011-08-17       Impact factor: 3.649

6.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Authors:  R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

7.  Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

Authors:  Belinda S Y Li; Juleiga Regal; Brian J Soher; Lois J Mannon; Robert I Grossman; Oded Gonen
Journal:  AJNR Am J Neuroradiol       Date:  2003-01       Impact factor: 3.825

8.  Diffusional kurtosis imaging of normal-appearing white matter in multiple sclerosis: preliminary clinical experience.

Authors:  Mariko Yoshida; Masaaki Hori; Kazumasa Yokoyama; Issa Fukunaga; Michimasa Suzuki; Koji Kamagata; Keigo Shimoji; Atsushi Nakanishi; Nobutaka Hattori; Yoshitaka Masutani; Shigeki Aoki
Journal:  Jpn J Radiol       Date:  2012-10-23       Impact factor: 2.374

Review 9.  MRI: role in optimising treatment.

Authors:  Anthony Traboulsee
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

10.  The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study.

Authors:  D T Chard; P A Brex; O Ciccarelli; C M Griffin; G J M Parker; C Dalton; D R Altmann; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-11       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.